Class / Patent application number | Description | Number of patent applications / Date published |
514040000 | Two saccharide radicals bonded through only oxygen to 4- and 6- positions of the cyclohexyl ring | 88 |
20080221049 | Free-flowing lyophilized tobramycin formulation - The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized tobramycin, wherein the lyophilized tobramycin is in the form of a free-flowing powder. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized tobramycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient. | 09-11-2008 |
20080227732 | Treatment and Control of Severe Infections Including Cystic Fibrosis - The present invention provides a pharmaceutical composition comprising antibiotic combination products for delivering two or more different antibiotics simultaneously, wherein the two different antibiotics comprise one which consisting of concentration dependent killing and the other concentration independent killing or time dependant killing activity. The invention has been worked out utilizing pharmacokinetic and pharmacodynamic principles to optimize antibiotic regimen, to improve clinical results and to potentially decrease the development of resistance. Combination of ceftazidime and tobramycin has been evolved to specifically illustrate the invention. | 09-18-2008 |
20090018091 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use - The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating | 01-15-2009 |
20090023668 | Method for treating blepharitis - The present invention is related to a method for treating blepharitis, the method comprising administering to an ocular area of a subject in need thereof a composition comprising about 0.001% to about 0.01% (w/v) dexamethasone and an antibiotic, wherein the composition is substantially free of lipids, and wherein the composition is ophthalmically acceptable. | 01-22-2009 |
20090042819 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use - The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating | 02-12-2009 |
20090082287 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES - The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration. | 03-26-2009 |
20090093423 | NOVEL 2-SUBSTITUTED METHYL PENAM DERIVATIVES -
Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them;
| 04-09-2009 |
20090156517 | STABLE PHARMACEUTICAL COMPOSITIONS OF AMINOGLYCOSIDE ANTIBIOTICS, ION-CHELATING AGENTS, AND BUFFERS - A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container. | 06-18-2009 |
20090156518 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTIC AND BUFFER - A pharmaceutical composition, comprising: at least one β-lactam antibiotic and at least one buffer component; wherein when the pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic mixed with the β-lactam antibiotic and the buffer component. | 06-18-2009 |
20090176720 | COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 07-09-2009 |
20090312279 | Antimicrobial compositions - An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials. | 12-17-2009 |
20090318378 | Antibiotic Combinations For Providing Total Solution to the Treatment of Infections - The invention relates to a new pharmaceutical composition, a method of treatment of infection and also a process to prepare the composition. The infectious complications are important causes of morbidity and mortality. Hospital acquired pneumonia (HAP) remains the most severe nosocomial infection in intensive care units. Beta-lactams alone are always considered inadequate when | 12-24-2009 |
20100087386 | TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION - The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided. | 04-08-2010 |
20100160247 | Synthesis of deuterated morpholine derivatives - The present invention is directed to a process for preparing a 2,26,6-d | 06-24-2010 |
20100204171 | MATERIALS AND METHODS FOR TREATING DISEASES CAUSED BY GENETIC DISORDERS USING AMINOGLYCOSIDES AND DERIVATIVES THEREOF WHICH EXHIBIT LOW NEPHROTOXICITY - Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health. | 08-12-2010 |
20100286078 | TOPICAL OPHTHALMIC COMPOSITIONS CONTAINING TOBRAMYCIN AND DEXAMETHASONE - Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage. | 11-11-2010 |
20100317607 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS - Compounds of a compound of compound of general formula (I) wherein X | 12-16-2010 |
20110082099 | Methods and Compositions for the Treatment of Cystic Fibrosis and Related Illnesses - The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are functionally redundant to the cystic fibrosis transmembrane conductance regulator (CFTR), allowing for the substrate conjugates to be exported from the cell. The export of GSH conjugates restores intracellular and extracellular levels of GSH to normal levels. Normalizing both extracellular and intracellular GSH via the increased conjugation of isothiocyanates with GSH, and subsequent export, can significantly rectify numerous enzymatic processes and correct the pathologies that are typical of patients suffering from cystic fibrosis. | 04-07-2011 |
20110166091 | Compositions Containing Piperacillin and Tazobactam Useful for Injection - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 07-07-2011 |
20110183932 | THREE-COMPONENT BONE CEMENT - A paste is provided from which bone cement can be formed, which is to the largest extent possible bubble-free and has a high impact strength. The paste includes (i) 15-50 weight percent of at least one mono-functional, hydrophobic methacrylic acid ester, (ii) 40-85 weight percent of at least one filler, (iii) 0.01-4 weight percent of at least one radical initiator soluble in the methacrylic acid ester (i) and having at least one peroxide group, (iv) 0.01-4 weight percent of at least one radical initiator soluble in the methacrylic acid ester (i) and having no peroxide groups, (v) 0.000001-3 weight percent of at least one accelerator soluble in the methacrylic acid ester (i) and capable of forming radicals from the radical initiators according to (iii) and (iv), (vi) 0.001-5 weight percent of at least one halide salt, and (vii) 0.2-3 weight percent of at least one cross-linking agent. | 07-28-2011 |
20110207687 | FULVIC ACID AND ANTIBIOTIC COMBINATION - This invention relates to a fulvic acid and antibiotic combination for use in the treatment of various diseases and conditions. The invention further relates to the use of the combination for the treatment of various diseases and conditions, including bacterial infection. In particular, the bacteria are antibiotic resistant bacteria. | 08-25-2011 |
20110212912 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 09-01-2011 |
20110230431 | FOSFOMYCIN/TOBRAMYCIN COMBINATIONS FOR THE TREATMENT AND PREVENTION OF OPHTHALMIC, OTOLOGICAL AND DERMATOLOGICAL INFECTIONS - Provided are topical fosfomycin-tobramycin compositions for the treatment and/or prevention of ophthalmic, otological, and dermatologic inflammation and/or bacterial infections and methods of treating ophthalmic, otological and dermatological inflammation and/or bacterial infections. | 09-22-2011 |
20110294753 | Means and methods for counteracting muscle disorders - The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival. | 12-01-2011 |
20120010162 | METHOD FOR TREATMENT OF LUNG INFECTIONS BY ADMINISTRATION OF AMINOGLYCOSIDES BY AEROLISATION - The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin. | 01-12-2012 |
20120077769 | TOPICAL OPHTHALMIC COMPOSITIONS CONTAINING TOBRAMYCIN AND DEXAMETHASONE - Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage. | 03-29-2012 |
20120135945 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 05-31-2012 |
20120135946 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 05-31-2012 |
20120135947 | OIL-IN-WATER EMULSION COMPOSITION CONTAINING DIFLUPREDNATE AND TOBRAMYCIN - The present invention provides an oil-in-water emulsion composition for topical administration, containing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier. Moreover, it provides a method for stabilizing tobramycin, which includes mixing (a) tobramycin, (b) difluprednate, (c) water, (d) oil and (e) an emulsifier to form an oil-in-water emulsion. The present invention can provide an oil-in-water emulsion composition containing tobramycin, which can maintain tobramycin content stably even when a non-ionic surfactant is added. | 05-31-2012 |
20120157398 | MATERIALS AND METHODS FOR TREATING DISEASES CAUSED BY GENETIC DISORDERS USING AMINOGLYCOSIDES AND DERIVATIVES THEREOF WHICH EXHIBIT LOW NEPHROTOXICITY - Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health. | 06-21-2012 |
20120165282 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): | 06-28-2012 |
20120184501 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 07-19-2012 |
20120184502 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 07-19-2012 |
20120225835 | ANTIBIOTIC FORMULATIONS, UNIT DOSES, KITS, AND METHODS - An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods. | 09-06-2012 |
20120329746 | TRIAZOL COMPOUNDS FOR TREATING BIOFILM FORMATION - The present invention relates to the use of a Compound of formula I | 12-27-2012 |
20130203693 | 4,6-SUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS - Aminoglycoside antibiotics of the formula | 08-08-2013 |
20130217642 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 08-22-2013 |
20130303475 | TOBRAMYCIN FORMULATION - This invention provides a pharmaceutical solution formulation comprising tobramycin, water, sodium chloride and sodium citrate, wherein the formulation has a pH of 4.5-7.0 and an osmolality of 135-200 mOsmol/Kg. | 11-14-2013 |
20130303476 | Aminoglycoside and Fosfomycin Combination for Treatment of Ventilator Associated Pneumonia (VAP) and Ventilator Associated Tracheal (VAT) Bronchitis - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 11-14-2013 |
20140005135 | STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS | 01-02-2014 |
20140011762 | High Throughput Screening for Antimicrobial Dosing Regimens - Provided herein are methods and computer-implemented systems for using computer simulations to predict likelihood of a cell population associated with a pathophysiological condition acquiring resistance to a therapeutic agent, to screen for therapeutic agents effective to suppress acquisition of resistance within a cell population and to treat the pathophysiological conditions associated therewith. The computer simulation comprises at least an input/out system and a mathematical model, including operably linked equations, parameter values and constant values, of growth response over a period of time of a cell population in contact with an therapeutic agent. Also provide is a method for determining a best-fit mathematical model of adaptation of a microbial population to a therapeutic agent over time and using the model to simulate microbial population behavior to a therapeutic agent. | 01-09-2014 |
20140038915 | METHODS FOR TREATING BACTERIAL INFECTION - This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix; incombination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant | 02-06-2014 |
20140073595 | AROMATIC AMIDES AS POTENTIATORS OF BIOEFFICACY OF ANTI-INFECTIVE DRUGS - The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms. | 03-13-2014 |
20140094424 | MICROBICIDAL COMPOSITIONS AND METHODS OF PRODUCTION USE THEREOF - Microbicidal compositions that exhibit enhanced microbial efficacy are disclosed, as well as methods of producing and using the microbicidal compositions. | 04-03-2014 |
20140206638 | PULMONARY DELIVERY OF AMINOGLYCOSIDE - The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections. | 07-24-2014 |
20140221302 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an in-line nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 08-07-2014 |
20140221303 | Hydraulic Cements, Methods and Products - Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous β-tricalcium phosphate (β-TCP) granules and at least one additional calcium phosphate powder. In another embodiment, the powder composition comprises calcium silicate powder. In a further embodiment, the powder composition comprises calcium aluminate powder. In another embodiment, the powder composition is a cement composition and comprises nanopowders having a grain size of less than 1 micron. Hardened cements are formed from such hydraulic cement compositions, and methods of producing hardened cements, kits, and articles of manufacture employ such hydraulic cement compositions. | 08-07-2014 |
20140256666 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS - The present invention describes single drug entities, formed by connecting an antibiotic moiety via a linker with a non-steroidal anti-inflammatory drug (NSAID) moiety. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual antibiotic and NSAID drug. | 09-11-2014 |
20140256667 | NOVEL TREATMENTS FOR ACTINIC KERATOSES - A composition of gentamicin and colchicine in a dermatologically acceptable cream base provided improved clearance of actinic keratoses following topical application for 1 to 3 months. The composition provides improved clearance of recalcitrant actinic keratoses. Furthermore, the treatment causes less pain and irritation than other topical treatments for actinic keratoses. | 09-11-2014 |
20140274933 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof: | 09-18-2014 |
20140315847 | DRUG ELUTING GRAFT CONSTRUCTS AND METHODS - The present invention provides, in certain aspects, medical graft products that incorporate multiple drug depots in and/or on the products. One such product is a sheet graft construct, for example for tissue support that includes a sheet graft material with a plurality of drug depots. The drug depots can be hardened deposits formed directly onto the sheet graft material and/or can be capable of eluting a drug for a minimum of 72 hours. | 10-23-2014 |
20140349956 | MATERIALS AND METHODS FOR DETECTING AND/OR PREDICTING NECROTIZING ENTEROCOLITIS IN INFANTS - The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC. | 11-27-2014 |
20140357592 | Composition - The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections. | 12-04-2014 |
20140378406 | SILVER BASED GELS FOR ANTIMICROBIAL APPLICATIONS - A pharmaceutical composition is prepared by mixing a cysteine-based monomer unit and a silver carbene complex. The cysteine-based monomer may be glutathione and the silver carbine complex may be provided according to particular formulae. The mixtures form gels and the gels may further include additional drug components. | 12-25-2014 |
20150045317 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 02-12-2015 |
20150057241 | FORMULATIONS OF AMINOGLYCOSIDES AND FOSFOMYCIN IN A COMBINATION HAVING IMPROVED CHEMICAL PROPERTIES - The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator. | 02-26-2015 |
20150057242 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 02-26-2015 |
20150099714 | SYNTHESIS OF DEUTERATED MORPHOLINE DERIVATIVES - The present invention is directed to a process for preparing a 2,26,6-d | 04-09-2015 |
20150299176 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof: | 10-22-2015 |
20150366196 | MICROBICIDAL COMPOSITIONS AND METHODS OF PRODUCTION USE THEREOF - Microbicidal compositions that exhibit enhanced microbial efficacy are disclosed, as well as methods of producing and using the microbicidal compositions. | 12-24-2015 |
20150366889 | PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA - Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria. | 12-24-2015 |
20160096835 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I or IA and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: | 04-07-2016 |
20160101088 | COMPOSITION INCLUDING RAPAMYCIN AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEARING LOSS - A pharmaceutical or health food includes rapamycin as an active ingredient, the pharmaceutical or health food being applied for prevention, improvement, and treatment of ototoxic hearing loss caused by an aminoglycoside-based antibiotic, sudden sensorineural hearing loss, and noise induced hearing loss. The pharmaceutical or health food is also applied to a pharmaceutical composite preparation of an aminoglycoside-based antibiotic and rapamycin, the pharmaceutical composite preparation reducing a side effect of the aminoglycoside-based antibiotic. | 04-14-2016 |
20160143847 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 05-26-2016 |
20160143932 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 05-26-2016 |
20160166601 | RE-EPITHELIALIZING PHARMACEUTICAL COMPOSITIONS COMPRISING XANTHAN GUM | 06-16-2016 |
20160188791 | TRANSCRIPTOME-WIDE DESIGN OF SELECTIVE, BIOACTIVE SMALL MOLECULES TARGETING RNA - Methods and computer systems are described herein for identifying small molecules that bind to selected RNA structural features (e.g., to RNA secondary structures). Also described are compounds and compositions that modulate RNA function and/or activity. | 06-30-2016 |
20160193344 | Fragmented Hydrogels | 07-07-2016 |
20160199328 | INTERMEDIATE METABOLISM PRODUCTS TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS IN BACTERIAL INFECTIONS | 07-14-2016 |
20170233388 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | 08-17-2017 |
20180021296 | POTENTIATED ANTIMICROBIAL AGENTS | 01-25-2018 |
514041000 | Kanamycin or derivative | 17 |
20080207538 | Enhanced Production of Functional Proteins From Defective Genes - This invention provides methods for enhancing production in a subject of a functional protein from a gene disrupted by a mutation, for example by the presence of a premature stop codon or by an exon skipping mutation, comprising administering to the subject an amount of an agent effective to suppress the mutation and an amount of an agent effective to increase transcription of the gene. | 08-28-2008 |
20090186841 | Novel aminoglycoside antibiotics - This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them. | 07-23-2009 |
20110034405 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF - The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. | 02-10-2011 |
20110034406 | System And Method For Controlling Bacterial Persister Cells With Weak Electric Currents - A system and method for treating persister cells with an electrochemical process, alone or in combination with antibiotics. Weak electric currents are used to effectively eliminate persister cells and the efficacy can be further improved through synergistic effects with antibiotics. The method may be adapted for novel therapies of chronic infections and strategies to control persistent biofouling. The system has a broad spectrum applications in treating chronic and drug resistant infections, such as those caused by | 02-10-2011 |
20110130357 | Aminoglycosides: Synthesis and Use as Antifungals - The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin B and kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease. | 06-02-2011 |
20110275587 | TOPICAL DELIVERY OF VISCOUS MEDICATIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CHRONIC SINUSITIS - A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient length of time for treatment of the affected area. This reduces the amount of wasted medication that would otherwise result from other topical methods. | 11-10-2011 |
20120135948 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): | 05-31-2012 |
20120165283 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS - This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them. | 06-28-2012 |
20120208781 | AMINOGLYCOSIDE DOSING REGIMENS - The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections. | 08-16-2012 |
20120316125 | AMINOGLYCOSIDES: SYNTHESIS AND USE AS ANTIFUNGALS - The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease. | 12-13-2012 |
20130053337 | GUANIDINYLATED AMINOGLYCOSIDE-LIPID CONJUGATES - Guanadinylated aminoglycoside-lipid conjugates are prepared. Such conjugates may comprise an aminoglycoside such as an aminoglyucoside antibiotic like neomycin or kanamycin, at least one guanidino group attached to a primary or secondary carbon atom of the aminoglyucoside group and at least one lipid group attached through a bond or a linker to a branched carbon atom of the aminoglycoside. These conjugates exhibit improve antibacterial activity and may be used in conjunction with another antibiotic. | 02-28-2013 |
20130096078 | NEW KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN - Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, | 04-18-2013 |
20130137652 | COMBINATION OF A PYRROLOQUINOLINE COMPOUND AND AN AMINOGLYCODISE ANTIMICROBIAL AGENT - This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with an aminoglycoside antimicrobial agent for the prevention and/or treatment of microbial infections. | 05-30-2013 |
20140200193 | THIXOTROPIC BIOLOGICAL ADHESIVE FOR USE IN INTERNAL BODY CAVITIES - A biological thixotropic adhesive that contains dextrin, and at least a structural component that provides thixotropy to the adhesive, and optionally at least an antibiotic that is very useful to stimulate the process of healing of tissues in a patient, for example, to prevent anastomotic leaks of the gastrointestinal system, to affix a prosthesis in inguinal hernioplasties, in a patient and to oclude a fistula in a patient. The biological thixotropic dahesive also has anti-inflammatory properties and can be used with a fatty tissue patch. | 07-17-2014 |
20140343005 | AQUEOUS COMPOSITIONS COMPRISING ARBEKACIN - The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride. | 11-20-2014 |
20150087612 | PHTHALOCYANINE COMPOUNDS USEFUL AS RECA INHIBITORS AND METHODS OF USING SAME - Compounds having the general structural formula (I) wherein X can be any element or compound that can form a coordination complex with phthalocyanine and wherein R1; R2, R3 and R4 are independently anionic moieties, or (II) wherein R1; R2, R3 and R4 are independently anionic moieties, are useful in the potentiation of antibiotic activity, and/or in inhibiting or delaying the development of resistance to antibiotics. R1; R2, R3 and R4 may be —S03-. The compounds may be administered to a subject in conjunction with an antibiotic. The antibiotic may be an activator of the SOS response, and may be a DNA gyrase inhibitor or a topoisomerase inhibitor. Compositions and dosage forms comprising the compounds are provided. | 03-26-2015 |
20160060285 | Aminoglycosides, Methods of Synthesis, and Associated Applications - A fungicidal compound that includes an aminoglycoside, or salt thereof, having the formula: | 03-03-2016 |